Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Lohberger, B; Glänzer, D; Etschmaier, V; Trajanoski, S; Leithner, A; Rinner, B; Georg, D.
Evaluation of crizotinib as radiosensitizer in sacral chordoma cells: effects of combined carbon ion particle therapy.
Med Oncol. 2025; 43(2): 59
Doi: 10.1007/s12032-025-03172-8
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Lohberger Birgit
- Co-Autor*innen der Med Uni Graz
- Etschmaier Vanessa
- Glänzer Dietmar
- Leithner Andreas
- Rinner Beate
- Trajanoski Slave
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Chordoma resection is challenging due to proximity to the brainstem or spinal cord, and chemotherapy offers limited efficacy. Combining surgery with radiotherapy, particularly using carbon ions (C-ions) for their higher biological effectiveness, improves local control and survival rates. To investigate cellular mechanisms, two human sacral chordoma cell lines were irradiated with varying C-ions doses. Growth, cell cycle, DNA damage response, and protein phosphorylation were analyzed using flow cytometry, protein, and gene expression profiling. The potential of combining treatment with the ALK/MET inhibitor crizotinib to enhance radiosensitivity was also evaluated. C-ions irradiation resulted in a slight dose-dependent decrease in proliferation, a clear G2/M cell cycle arrest, and a significant activation of key regulators involved in DNA repair and damage response. The ALK/MET inhibitor crizotinib, considered a potential treatment for chordomas, reduced proliferation markers and modulated important genes related to DNA repair and cell cycle regulation, with CDC20 and FOXO4 being particularly significant. The phosphorylation of key regulators involved in DNA repair and damage prevention, as well as MAPKs activated by C-ions irradiation, was partially inhibited by the combination treatment with crizotinib. While crizotinib shows promise as a therapeutic agent for sacral chordomas, its capacity to enhance radiosensitivity appears limited.
- Find related publications in this database (using NLM MeSH Indexing)
- Humans - administration & dosage
- Crizotinib - administration & dosage
- Chordoma - pathology, radiotherapy, drug therapy, therapy
- Heavy Ion Radiotherapy - methods
- Pyridines - pharmacology
- Cell Line, Tumor - administration & dosage
- Pyrazoles - pharmacology
- Radiation-Sensitizing Agents - pharmacology
- Sacrum - pathology, drug effects
- Cell Proliferation - drug effects, radiation effects
- Spinal Neoplasms - pathology, radiotherapy
- Cell Cycle - drug effects, radiation effects
- DNA Damage - drug effects
- Protein Kinase Inhibitors - pharmacology
- Find related publications in this database (Keywords)
- Sacral chordoma
- Carbon ions irradiation
- Crizotinib
- DNA repair mechanisms